Mendus AB IMMU
OMXSTO · Sweden · Health Technology
SEK 6.33-0.02 (-0.31%)
Market open· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Mendus AB (FRA:1YG0) reports reduced costs and extended cash runway while advancing key trials in AML and CML, positioning for significant clinical milestones through 2027.
Mendus AB (STU:1YG0) showcases positive trial data and strategic financial moves, despite facing ongoing financial hurdles and market uncertainties.
London, United Kingdom--(Newsfile Corp. - November 21, 2025) - Edison issues report on Mendus (OMX: IMMU).We have updated our investment view on Mendus following its expanded strategy for vididencel to chronic myeloid leukaemia (CML) and a broader acute myeloid leukaemia (AML) population, including chemo-eligible and chemo-ineligible patients, regardless of their measurable residual disease (MRD) status. In our view, this is a bold strategic pivot for a programme nearing Phase III readiness, but
Mendus AB (FRA:1YG0) reports promising trial expansions and patent gains amidst financial hurdles and strategic adjustments.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.